Please note: This trial has finished recruiting and is not accepting new participants.

Research Center: University of Adelaide, Adelaide Health & Medical Sciences Building
Location: 4 North Terrace, Adelaide SA 5000, Australia
Lead Researcher: Professor Karen Jones
Ethics Committee: This study has been reviewed and approved by the Central Adelaide Local Health Network Human Research Ethics Committee

Background

 

Exenatide (Byetta) is an FDA-approved medication for managing blood sugar levels in people with Type 2 Diabetes. At present, it is typically administered twice daily.

A longer-acting, weekly dose of this medication is being studied at the University of Adelaide to further explore how the treatment  slows down the process of food emptying from the stomach thereby causing blood sugar levels to go down and the effects on the body between the two actions. 

This study seeks men and women who are currently diagnosed with Type 2 Diabetes. Participants are required to attend 8 study visits at the research site over a 2-month period and will be compensated up to $420 for participating in this study.

Why Participate? 

 

• You may experience an improvement in your blood sugar levels.
• You will be compensated up to $420 for participating in this study.
• You will be helping to provide more information about the once weekly treatment option for those with Type 2 Diabetes.
• You will be helping to advance medical research in Type 2 Diabetes.

Your Rights

 

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time without affecting your medical care.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

Who Can Participate?

 

• Men and women aged 40-80 who have Type 2 Diabetes not taking medication to control their blood pressure.
• Able to attend a 2hr screening visit to determine eligibility, 2 study visits at the research site between 9am-5pm during weekdays and 8 weekly visits of approximately 1hr duration, over approximately ~3 months.
• Currently managing Type 2 Diabetes via diet or metformin.
• Willing to fast overnight (14 hours for solids, 12 hours for liquids) for 2 study day visits and the screening visit.
• Comfortable with needles (the study medication is administered as an injectable)